– Seasoned public company CFO with deep biopharmaceutical finance experience across commercial operations, R&D portfolio management, investor relations, and capital allocation – 

SAN DIEGO, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA, "Kura"))), a biopharmaceutical company focused on precision medicines for the treatment of cancer, today announced the appointment of Jennifer Fulk as Chief Financial Officer, effective September 8, 2026. Ms. Fulk will join Kura’s senior leadership team and report to Troy Wilson, Ph.D., J.D., President, Chief Executive Officer and Chairman of the Board.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.